Literature DB >> 9150289

Neomycin and gadolinium applied to an L5 spinal nerve lesion prevent mechanical allodynia-like behaviour in rats.

K H Blenk1, H J Häbler, W Jänig.   

Abstract

In male Wistar rats, the left ventral ramus of the L5 spinal nerve (RvL5) was cut, and animals were tested for allodynia-like behaviour in response to mechanical stimuli which were applied with von Frey hairs (4.3-205 mN) to the plantar skin of the hindpaw supplied by the intact L4 spinal nerve. After surgery, allodynia-like behaviour was evoked prominently on the operated (left) side and weakly on the contralateral (right) side. Eleven sham-operated rats displayed low levels of allodynia-like behaviour on the operated side comparable to that seen contralateral to the lesion in nerve-transected animals. In 14 rats, allodynic behaviour to mechanical stimuli on either side was dose dependently and permanently reduced, after 4-32 mg of the antibiotic Nebacetin had been applied locally at the transection site immediately after cutting the nerve. The same effect was observed when one of the active compounds of Nebacetin, neomycin, but not the other, bacitracin, was applied by continuous local infusion. Allodynia-like behaviour to stimuli between 4.3 mN and 124 mN was also prevented when 1-8 mg gadolinium acetate was applied at the transection site, whereas allodynic behaviour to stimuli of 205 mN was not affected at least for the first 7 days after the lesion. Both gadolinium and Nebacetin failed to prevent allodynic behaviour when applied later than 7 h after the nerve lesion. Neither substance interfered with the development of tactile allodynia when applied to the nerve rostral to the lesion site. The results suggest that Nebacetin and gadolinium interfere with the mechanisms at the RvL5 transection site crucial for the initiation of sensitisation of dorsal horn neurones and the development of mechanical allodynia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150289     DOI: 10.1016/s0304-3959(96)03314-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  8 in total

1.  Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials.

Authors:  Ron Amir; Martin Michaelis; Marshall Devor
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 2.  Ectopic discharge in Abeta afferents as a source of neuropathic pain.

Authors:  Marshall Devor
Journal:  Exp Brain Res       Date:  2009-02-26       Impact factor: 1.972

Review 3.  Arbiters of endogenous opioid analgesia: role of CNS estrogenic and glutamatergic systems.

Authors:  Alan R Gintzler; Nai-Jiang Liu
Journal:  Transl Res       Date:  2021-02-07       Impact factor: 7.012

4.  Neuronal loss in the rostral ventromedial medulla in a rat model of neuropathic pain.

Authors:  Mai Lan Leong; Ming Gu; Rebecca Speltz-Paiz; Eleanor I Stahura; Neli Mottey; Clifford J Steer; Martin Wessendorf
Journal:  J Neurosci       Date:  2011-11-23       Impact factor: 6.167

5.  Opposing effects of spinal nerve ligation on calcium-activated potassium currents in axotomized and adjacent mammalian primary afferent neurons.

Authors:  Constantine D Sarantopoulos; J Bruce McCallum; Marcel Rigaud; Andreas Fuchs; Wai-Meng Kwok; Quinn H Hogan
Journal:  Brain Res       Date:  2006-12-20       Impact factor: 3.252

6.  Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy.

Authors:  Haijun Zhang; Patrick M Dougherty
Journal:  Anesthesiology       Date:  2014-06       Impact factor: 7.892

7.  Pharmacological Modulation of Endogenous Opioid Activity to Attenuate Neuropathic Pain in Rats.

Authors:  Nai-Jiang Liu; Emiliya M Storman; Alan R Gintzler
Journal:  J Pain       Date:  2018-10-23       Impact factor: 5.820

8.  Sex Differences in a Rat Model of Peripheral Neuropathic Pain and Associated Levels of Endogenous Cannabinoid Ligands.

Authors:  Laura Boullon; David P Finn; Álvaro Llorente-Berzal
Journal:  Front Pain Res (Lausanne)       Date:  2021-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.